Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
35060 | 103 | 37.3 | 92% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
227 | 3 | MICRORNA//MIRNA//GENE DELIVERY | 49432 |
57 | 2 | MICRORNA//MIRNA//LONG NONCODING RNAS | 29594 |
35060 | 1 | MIR 494//MIR 503//MICRORNA 503 | 103 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MIR 494 | authKW | 6072975 | 25% | 79% | 26 |
2 | MIR 503 | authKW | 3567416 | 18% | 63% | 19 |
3 | MICRORNA 503 | authKW | 1334077 | 6% | 75% | 6 |
4 | MIR 448 | authKW | 474335 | 4% | 40% | 4 |
5 | MICRORNA 494 | authKW | 333516 | 3% | 38% | 3 |
6 | ARHGEF19 | authKW | 296462 | 1% | 100% | 1 |
7 | BAYLOR MED DALLAS | address | 296462 | 1% | 100% | 1 |
8 | CELL DIFFERENTIAT OPTOSIS MINIS | address | 296462 | 1% | 100% | 1 |
9 | CINOBUFACIN | authKW | 296462 | 1% | 100% | 1 |
10 | ENDOCRINOL ONCOL SPERIMENTALE IEOS CONSIGLIO NA | address | 296462 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 692 | 43% | 0% | 44 |
2 | Medicine, Research & Experimental | 453 | 25% | 0% | 26 |
3 | Cell Biology | 114 | 18% | 0% | 19 |
4 | Biophysics | 36 | 8% | 0% | 8 |
5 | Biochemistry & Molecular Biology | 31 | 18% | 0% | 19 |
6 | Gastroenterology & Hepatology | 29 | 6% | 0% | 6 |
7 | Pathology | 13 | 4% | 0% | 4 |
8 | Genetics & Heredity | 3 | 4% | 0% | 4 |
9 | Biotechnology & Applied Microbiology | 3 | 4% | 0% | 4 |
10 | Mathematical & Computational Biology | 1 | 1% | 0% | 1 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BAYLOR MED DALLAS | 296462 | 1% | 100% | 1 |
2 | CELL DIFFERENTIAT OPTOSIS MINIS | 296462 | 1% | 100% | 1 |
3 | ENDOCRINOL ONCOL SPERIMENTALE IEOS CONSIGLIO NA | 296462 | 1% | 100% | 1 |
4 | HEAVY LON RADIAT BIOL MED | 296462 | 1% | 100% | 1 |
5 | HUMAN GENOME CARDIO X | 296462 | 1% | 100% | 1 |
6 | INSERM U1081CNRS UMR7284IRCAN | 296462 | 1% | 100% | 1 |
7 | LIFE SCI TECHNOL GENET DEV BIOL | 296462 | 1% | 100% | 1 |
8 | MED GASTROENTEROLCANC HOSP HENAN PROV | 296462 | 1% | 100% | 1 |
9 | PEDIAT BIOCHIM BIOL MOL | 296462 | 1% | 100% | 1 |
10 | PERTH BLOOD | 296462 | 1% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | M S-MEDECINE SCIENCES | 12827 | 12% | 0% | 12 |
2 | TUMOR BIOLOGY | 1202 | 5% | 0% | 5 |
3 | AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 1087 | 2% | 0% | 2 |
4 | TRANSLATIONAL CANCER RESEARCH | 880 | 1% | 0% | 1 |
5 | NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES A, LIFE SCIENCES | 824 | 1% | 0% | 1 |
6 | ONCOLOGY REPORTS | 742 | 5% | 0% | 5 |
7 | MEDICAL SCIENCE MONITOR | 610 | 3% | 0% | 3 |
8 | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 469 | 3% | 0% | 3 |
9 | BRIEFINGS IN BIOINFORMATICS | 425 | 1% | 0% | 1 |
10 | ONCOTARGET | 382 | 4% | 0% | 4 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MIR 494 | 6072975 | 25% | 79% | 26 | Search MIR+494 | Search MIR+494 |
2 | MIR 503 | 3567416 | 18% | 63% | 19 | Search MIR+503 | Search MIR+503 |
3 | MICRORNA 503 | 1334077 | 6% | 75% | 6 | Search MICRORNA+503 | Search MICRORNA+503 |
4 | MIR 448 | 474335 | 4% | 40% | 4 | Search MIR+448 | Search MIR+448 |
5 | MICRORNA 494 | 333516 | 3% | 38% | 3 | Search MICRORNA+494 | Search MICRORNA+494 |
6 | ARHGEF19 | 296462 | 1% | 100% | 1 | Search ARHGEF19 | Search ARHGEF19 |
7 | CINOBUFACIN | 296462 | 1% | 100% | 1 | Search CINOBUFACIN | Search CINOBUFACIN |
8 | FIBROBLAST GROWTH RECEPTOR 2 | 296462 | 1% | 100% | 1 | Search FIBROBLAST+GROWTH+RECEPTOR+2 | Search FIBROBLAST+GROWTH+RECEPTOR+2 |
9 | KANGAI 1 | 296462 | 1% | 100% | 1 | Search KANGAI+1 | Search KANGAI+1 |
10 | LYSINE K SPECIFIC DEMETHYLASE 2B | 296462 | 1% | 100% | 1 | Search LYSINE+K+SPECIFIC+DEMETHYLASE+2B | Search LYSINE+K+SPECIFIC+DEMETHYLASE+2B |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | XIAO, Y , TIAN, QG , HE, JT , HUANG, M , YANG, C , GONG, LS , (2016) MIR-503 INHIBITS HEPATOCELLULAR CARCINOMA CELL GROWTH VIA INHIBITION OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR.ONCOTARGETS AND THERAPY. VOL. 9. ISSUE . P. 3535 -3544 | 13 | 50% | 1 |
2 | TAY, J , TIAO, J , HUGHES, Q , GILMORE, G , BAKER, R , (2016) THERAPEUTIC POTENTIAL OF MIR-494 IN THROMBOSIS AND OTHER DISEASES: A REVIEW.AUSTRALIAN JOURNAL OF CHEMISTRY. VOL. 69. ISSUE 10. P. 1078 -1093 | 29 | 21% | 1 |
3 | ZHAO, XJ , ZHOU, Y , CHEN, Y , YU, F , (2016) MIR-494 INHIBITS OVARIAN CANCER CELL PROLIFERATION AND PROMOTES APOPTOSIS BY TARGETING FGFR2.ONCOLOGY LETTERS. VOL. 11. ISSUE 6. P. 4245 -4251 | 13 | 42% | 3 |
4 | JIANG, XK , CHEN, Y , DU, E , YANG, K , ZHANG, ZH , QI, SY , XU, Y , (2016) GATA3-DRIVEN EXPRESSION OF MIR-503 INHIBITS PROSTATE CANCER PROGRESSION BY REPRESSING ZNF217 EXPRESSION.CELLULAR SIGNALLING. VOL. 28. ISSUE 9. P. 1216 -1224 | 13 | 35% | 1 |
5 | WANG, J , CHEN, HT , LIAO, YF , CHEN, N , LIU, TZ , ZHANG, HT , ZHANG, HY , (2015) EXPRESSION AND CLINICAL EVIDENCE OF MIR-494 AND PTEN IN NON-SMALL CELL LUNG CANCER.TUMOR BIOLOGY. VOL. 36. ISSUE 9. P. 6965 -6972 | 9 | 47% | 8 |
6 | LI, N , ZHAO, XS , WANG, LF , ZHANG, S , CUI, MH , HE, J , (2016) MIR-494 SUPPRESSES TUMOR GROWTH OF EPITHELIAL OVARIAN CARCINOMA BY TARGETING IGF1R.TUMOR BIOLOGY. VOL. 37. ISSUE 6. P. 7767 -7776 | 9 | 33% | 5 |
7 | LIU, K , LIU, SY , ZHANG, W , JIA, BX , TAN, LD , JIN, Z , LIU, YH , (2015) MIR-494 PROMOTES CELL PROLIFERATION, MIGRATION AND INVASION, AND INCREASED SORAFENIB RESISTANCE IN HEPATOCELLULAR CARCINOMA BY TARGETING PTEN.ONCOLOGY REPORTS. VOL. 34. ISSUE 2. P. 1003 -1010 | 11 | 27% | 16 |
8 | ZHI, XD , WU, K , YU, DS , WANG, YS , YU, Y , YAN, P , LV, G , (2016) MICRORNA-494 INHIBITS PROLIFERATION AND METASTASIS OF OSTEOSARCOMA THROUGH REPRESSING INSULIN RECEPTOR SUBSTRATE-1.AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH. VOL. 8. ISSUE 8. P. 3439 -3447 | 10 | 33% | 1 |
9 | LI, JY , WANG, LJ , LIU, ZZ , ZU, C , XING, FF , YANG, P , YANG, YK , DANG, XQ , WANG, KZ , (2015) MICRORNA-494 INHIBITS CELL PROLIFERATION AND INVASION OF CHONDROSARCOMA CELLS IN VIVO AND IN VITRO BY DIRECTLY TARGETING SOX9.ONCOTARGET. VOL. 6. ISSUE 28. P. 26216 -26229 | 10 | 30% | 11 |
10 | DUTTA, P , HALLER, E , SHARP, A , NANJUNDAN, M , (2016) MIR494 REDUCES RENAL CANCER CELL SURVIVAL COINCIDING WITH INCREASED LIPID DROPLETS AND MITOCHONDRIAL CHANGES.BMC CANCER. VOL. 16. ISSUE . P. - | 13 | 26% | 0 |
Classes with closest relation at Level 1 |
Rank | Class id | link |
---|---|---|
1 | 88 | MICRORNA//MIR 21//MIRNA |
2 | 29445 | ZNF217//CTBP//CTBP1 |
3 | 23849 | MIR 218//MICRORNA 218//MIR 214 |
4 | 14661 | MIR 124//GLIOMA//MIR 128 |
5 | 20409 | MIR 506//MICRORNA 130B//MIR 200C |
6 | 21570 | MIR 210//MICRORNA 210//C19MC |
7 | 8182 | MIR 122//MICRORNA 122//MICRORNA |
8 | 33345 | MIR 101//MIR 26B//MICRORNA 101 |
9 | 15912 | MIR 34A//MIR 449A//MICRORNA 34A |
10 | 37472 | MIR 22//MIR 22 3P//AUTHOR OUTPATIENT |